

HEMOSENSE INC  
Form S-8 POS  
November 06, 2007

As filed with the Securities and Exchange Commission on November 6, 2007

Registration No. 333-139067

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM S-8

REGISTRATION STATEMENT

*Under*

*The Securities Act of 1933*

---

## HEMOSENSE, INC.

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

651 River Oaks Parkway

San Jose, California 95134

(408) 719-1393

(Address including zip code, and telephone number, including area code, of principal executive offices)

**77-0452938**  
(I.R.S. Employer

Identification Number)

---

**2005 EQUITY INCENTIVE PLAN**

**(Full title of the plan)**

---

**James D. Merselis**

**President and Chief Executive Officer**

**HemoSense, Inc.**

**651 River Oaks Parkway**

**San Jose, California 95134**

**(408) 719-1393**

**(Name, address, and telephone number, including area code, of agent for service)**

---

## Edgar Filing: HEMOSENSE INC - Form S-8 POS

---

The Registration Statement on Form S-8 (Registration No. 333-139067) (the Registration Statement ) of HemoSense, Inc. ( HemoSense ) pertaining to the registration of certain shares of HemoSense s common stock, \$0.001 par value per share ( HemoSense Common Stock ), issuable to eligible employees, directors and consultants of HemoSense under its 2005 Equity Incentive Plan, to which this Post-Effective Amendment No. 1 relates, was filed with the Securities and Exchange Commission on December 1, 2006.

HemoSense, Inverness Medical Innovations, Inc. ( Inverness ) and Spartan Merger Sub, Inc., a wholly owned subsidiary of Inverness ( Merger Sub ), entered into an Agreement and Plan of Reorganization, dated as of August 6, 2007 (the Merger Agreement ), that provides for, among other things, the merger of Merger Sub with and into HemoSense, with HemoSense surviving as a wholly owned subsidiary of Inverness, and the conversion of each outstanding share of HemoSense Common Stock into the right to receive 0.274192 shares of common stock, par value \$0.001 per share, of Inverness (the Merger ).

The Merger was completed on November 6, 2007.

As a result of the Merger, HemoSense has terminated all offerings of HemoSense Common Stock pursuant to its existing registration statements, including the Registration Statement. Accordingly, HemoSense hereby removes from registration all shares of HemoSense Common Stock registered under the Registration Statement which remain unsold as of the time of the Merger.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Jose, California, on November 6, 2007.

**HEMOSENSE, INC.**

By: /s/ James D. Merselis  
James D. Merselis  
President and Chief Executive Officer